Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults (Q45398885)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 November 2007

Language	Label	Description	Also known as
English	Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults	scientific article published on 20 November 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

0 references

1 reference

based on heuristic

inferred from title

object named as

Guido Ferrari

Ferrari, G.

5

0 references

Lindsey R Baden

2

object named as

Lindsey R Baden

Baden, L. R.

Baden, L.R.

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Tonya Villafana

8

object named as

Tonya L Villafana

Villafana, T. L.

Villafana, T.L.

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

HIV Vaccine Trials Network

12

object named as

HIV Vaccine Trials Network

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Geoffrey J Gorse

1

object named as

Geoffrey J Gorse

Gorse, G. J.

Gorse, G.J.

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Nina D. Russell

11

object named as

Nina D Russell

Russell, N. D.

Russell, N.D.

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

3

object named as

Margaret Wecker

Wecker, M.

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Elizabeth Noonan

10

object named as

Noonan, E.

Elizabeth Noonan

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Kent J. Weinhold

6

object named as

Kent J Weinhold

Weinhold, K. J.

Weinhold, K.J.

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

author name string

Mark J Newman

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Brian D Livingston

7

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Hongli Li

9

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Newman, M. J.

4

0 references

Livingston, B. D.

7

0 references

Li, H.

9

0 references

Newman, M.J.

4

0 references

Livingston, B.D.

7

0 references

language of work or name

0 references

publication date

20 November 2007

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

2008

0 references

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Clinical and Vaccine Immunology

0 references

26

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

215-223

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

http://ugspace.ug.edu.gh/handle/123456789/846

0 references

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

DNA vaccines against human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Development of a DNA Vaccine Designed to Induce Cytotoxic T Lymphocyte Responses to Multiple Conserved Epitopes in HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Identification of most frequent HLA class I antigen specificities in Botswana: relevance for HIV vaccine design.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Oligoclonal expansions of CD8(+) T cells in chronic HIV infection are antigen specific.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Functional genomics Double-stranded RNA poses puzzle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Recognition of a small number of diverse epitopes dominates the cytotoxic T lymphocytes response to HIV type 1 in an infected individual

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Characterization of an in situ IFN-gamma ELISA assay which is able to detect specific peptide responses from freshly isolated splenocytes induced by DNA minigene immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Synergistic effect of formulated plasmid and needle-free injection for genetic vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Protective interactive noncondensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Polyvinyl derivatives as novel interactive polymers for controlled gene delivery to muscle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human Subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Evaluation of cellular immune responses in subjects chronically infected with HIV type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.10.061

7 January 2021

Identifiers

10.1016/J.VACCINE.2007.10.061

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

University of Ghana Digital Collections (UGSpace) ID

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45398885&oldid=2211891226"